Tropical Health Matters

Adegbola and colleagues note that “the efficacy of SP-IPTp is threatened by the emergence of sulfadoxine-pyrimethamine resistant malaria parasites, “which has been observed in East Africa. They therefore, studied the situation in Nigeria, the country with the highest malaria burden in the continent. Their study showed that “the prevalence of VAGKGS haplotype seems to be increasing in prevalence.”

In conclusion, they worried that, “If this is similar in effect to the emergence of 581G in East Africa, the efficacy of SP-IPTp in the presence of these novel Pfdhps mutants should be re-assessed” in Nigeria. This situation threatens the use of sulfadoxine-pyrimethamine (SP) in two major prevention programs including intermittent preventive treatment during pregnancy (IPTp) and seasonal malaria chemoprevention (SMC) for children.

The benefits of IPTp using SP is the ability to administer chemoprevention in a single directly observed dose. Alternative medications are being explored, but from the behavioral intervention perspective, the low cost and simplicity afforded by SP is ideal.

The IPTp strategy had been modified a decade ago from requiring 2 doses, to monthly doses from the second trimester onwards because of parasite resistance or what is also termed drug tolerance by the parasite. Tolerance implies that the drug may still work, but at higher or more frequent doses. Such changes have cost and behavior change implications. Many country reports from the Malaria Indicator Surveys show an expected drop-off in uptake of SP between the first and third doses. For example in the 2021 Nigeria MIS IPTp1 uptake was 58%, while IPTp3 had reduced to 31%.

A related problem in Nigeria is the ubiquitous availability of SP in medicine shops across the country in contrast to official policy limiting it to use in IPTp and SMC. The challenge is finding affordable and feasible alternative medicines for IPTp. In the meantime, we have not even reached coverage targets using SP nor fully achieved rollout of companion interventions such as the use of Insecticide Treated Nets. Much work is still needed to protect pregnant women and fetuses from the malaria induced problems of anemia, low-birth-weight, stillbirth, and more.

A related study from Cameroon: The occurrence of sub-microscopic P. falciparum parasites resistant to SP and intense malaria transmission poses persistent risk of malaria infection during pregnancy in the area. ITN usage and 
monitoring spread of resistance are critical.

https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04485-7

Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, reminds us in this year’s edition of the World Malaria Report (WMR 2022) that, “Although hard hit, most countries held the line and were able to maintain services to prevent, detect and treat malaria – a remarkable feat in the midst of a pandemic. Nonetheless, more than 600 000 people still die of malaria every year – most of them children. Even with the heroic efforts to maintain services during the pandemic, malaria control efforts face many hurdles in addition to the already significant COVID-related disruptions and other health system challenges.”

Even though there was an increase in cases between 2020 and 2021, there are now more strategies in the malaria control and elimination toolkit than ever before. One in particular is an updated take on an old concept of chemoprophylaxis, which fell out of use due to mounting drug resistance. Years of research with pregnant women and young children led to the development over time of using regularly scheduled treatment doses of malaria medicines as chemoprevention. Intermittent Preventive Treatment for pregnant women (IPTp) and Seasonal Malaria Chemoprevention for young children, both targeted to appropriate epidemiological settings, are now common. Countries are also exploring IPT for children in other settings.

We were, therefore, curious what the current WMR shares on chemoprevention initiatives. Specifically, the WMR summarized WHO recommendations as follows: “Updated guidelines provide recommendations on intermittent preventive treatment of malaria in pregnancy (IPTp), perennial malaria chemoprevention (PMC) and seasonal malaria chemoprevention (SMC), intermittent preventive treatment of malaria in school-aged children (IPTsc), post-discharge malaria chemoprevention (PDMC), mass drug administration (MDA) and elimination.”

In summary, WMR 2022 notes that, “The average number of children treated per cycle of SMC increased from about 0.2 million in 2012 to almost 45 million in 2021,” and “Using data from 33 countries in the WHO African Region, the percentage of IPTp use by dose was computed. In 2021, 72% of pregnant women used ANC services at least once during their pregnancy. About 55% of pregnant women received one dose of IPTp, 45% received two doses and 35% received three doses.” This is not just progress over time, but also represents an expansion targets and work required for success. For pregnant women the increase represented a change in target from only two doses during pregnancy to a minimum of three. Starting with pilot efforts, SMC now covers children in 15 countries.

The targeted three doses for IPTp shows that two thirds of women who register for antenatal (prenatal) care (ANC), fail to achieve full coverage. Stronger collaboration is needed between malaria control and maternal health programs to ensure that pregnant women actually attend ANC and do so early and often enough to receive 3 monthly doses minimum in their second and third trimesters. More emphasis is needed on community IPTp distribution, since we know that community health workers have been crucial in achieving SMC as well as integrated community case management efforts.

Similar challenges exist for SMC as research looks into whether additional doses are needed based on mosquito breeding and malaria transmission season factors in endemic countries. Adding extra months to the program will tax resources, but also save lives.

Both maternal and child efforts at chemoprevention will need to address research that first shows increasing resistance to the common medicines used, and the potential for introducing new drug combinations in light of that resistance. Challenges here reflect another aspect of SMC, the need for CHWs to guarantee that on any given distribution round, three doses on medicine are required. Recent reports show that within any given round, community adherence to SMC has been good. We need to apply those lessons to IPTp when the regimen changes.

Ultimately, chemoprevention has proven to be an important life saving tool. The challenges of multiple contacts and doses that lead to success rely not only on having effective medicines, but also on culturally appropriate behavior change strategies and well-funded efforts to strengthen the health systems that deliver preventive treatments.

Jean Louis Ndikumana Mangara, Marcel Manariyo, Michée S. Kabera, Yvette Muyirukazi, Jean Modeste Harerimana, Christine Mutaganzwa, Marie Rose Kayirangwa, Noella Umulisa, Aimable Mbituyumuremyi report on Improving insecticide treated net coverage through antenatal care services in Rwanda at the 2022 Annual Meeting of the American Society of Tropical Medicine and Hygiene.

Malaria in pregnancy (MIP) negatively affects pregnancy outcomes, including maternal and neonatal mortality and adverse fetal outcomes such as low birth weight. Therefore, among other malaria prevention interventions, Rwanda embarked to achieve the insecticide treated net (ITN) universal coverage through the ITN mass distribution to households and routine distribution to the most vulnerable groups including under five children and pregnant women.

In the period of Jan 2020 to Dec 2021, the program improved ITN distribution and the information, education and communication on challenges related to malaria behavior during ANC visits and conducted capacity building of health care providers on malaria diagnostic and case management training, integrated malaria supportive supervision, monthly data review and validation meetings at health facilities and monitoring of use of ITN program at health facility level.

A quarterly review of data from national Health Management Information System (HMIS) on ITN distributed during ANC services and changes in MIP incidence was done in the period of January 2020 to December 2021. The results show an increase from 49% (z-score (-0.8)) (Jan-Mar 2020) to 74% (z-score 0.5) (Oct-Dec 2021) coverage in the distribution of ITN among pregnant women during ANC visits.

There was a decrease in malaria incidence from 65 (z-score (2)) to 17 (z-score (-1)) cases among pregnant visiting ANC services, and a decrease from 88 to 73 malaria cases in all (567,198) pregnant women for10,000 confirmed malaria case during the January-March 2020 to October-December 2021. There has been a moderate negative correlation between the proportion of pregnant women receiving ITN in ANC services and the proportion of malaria cases in pregnancy every quarter r(9) = -0.655, P (value)=0.056.

Although malaria cases among pregnant women have declined and the distribution of ITN in ANC services increased over the studied period, there is a need to strategize innovation to reach the remaining pregnant women.

San Barro, Ousmane Badolo, Mathurin Bonzi, Moumouni Bonkoungou Youssouf Sawadogo, Andre Kone, Thierry Ouedraogo, Mathurin Dodo, Lolade Oseni, Gladys Tetteh, and William Brieger explain an innovation of Sponsorship of target children during the Seasonal Malaria Chemoprevention (SMC) campaign in order to improve malaria prevention follow-up and coverage in the Reo health district of Burkina Faso in 2021.

Malaria is a major public health problem in Burkina Faso. According to health statistics for 2020, malaria accounted for 39.8% of health center consultations, 54.1% of hospitalizations and 27.4% of deaths. Children under 5 years of age pay the highest toll with 72.4% of deaths.

In 2021, the Reo Health District and the other six districts of the Centre-Ouest region were supported by the PMI Impact Malaria Project to implement Seasonal Malaria Chemoprevention (SMC). This includes monthly preventive doses of Sulfadoxine-pyrimethamine/amodiaquine for 4 months during the main malaria transmission season. A recent multi-country article in The Lancet showed that while 75% of eligible children received a dose in any given month, only 53% received a dose on all four months.

Coverage reports indicate that better follow-up is needed once children start the SMC process. Thus, during the SMC Campaign, the district management team introduced an innovation  consisting of “sponsorship” of SMC target children as a new follow-up mechanism. These sponsors are Community Distributors (CDs) or Community Based Organizations (CBOs). They voluntarily agreed to follow up with five children each, between July and October 2021 in order …

1. To ensure that the children actually took the medication
2. To monitor whether these children did not get sick between two cycles
3. To inform the nurse in charge of the health center in case of illness of a sponsored child
4. To encourage parents to use bed nets to protect their children. In total, 1468 children were monitored and 224 (15.26%) had malaria.

This innovation on SMC distribution contributed to protect 84% of the children. Challenges include the lack of financial resources to support the sponsors and the inaccessibility of some areas due to the rains. When medicines are correctly administered to children and they are regularly monitored, protection is better.

Moumouni Bonkoungou, Ousmane Badolo, Mathurin Bonzi, Youssouf Sawadogo, Andre Kone, Thierry Ouedraogo, Mathurin Dodo, Lolade Oseni, Gladys Tetteh, and William Brieger shared information on ?Evaluation of the Implementation of Seasonal Malaria Chemoprevention (SMC) through Independent Monitoring in Burkina Faso during the 2022 Annual Meeting of the American Society of Tropical Medicine and Hygiene.?

In Burkina Faso, malaria is the leading cause of children < 5 morbidity (40.6% of severe cases), and 72.4% of death   in 2020. Seasonal malaria chemoprevention (SMC) was recommended by WHO in 2012, and since 2014, it has been implemented in Burkina Faso. SMC consists monthly doses (03 doses) of Amodiaquine Plus Sulfadoxine-Pyrimethamine to all eligible children (3-59 months) during the season of high malaria transmission.

To ensure the quality of the intervention and the coverage achieved, two independent monitoring surveys were conducted at the first (C1) and fourth (C4) rounds (of 2020?). In order to minimize bias, non-health care workers (mainly teachers) were recruited, trained and supervised for the purpose of this survey.

Monitoring was conducted in 43 districts, including 19 in the PMI/USAID Impact Malaria project area, where 838,000 children received treatment. The number of children seen in the houses was 6752 at C1 and 6608 at C4 (10 houses per selected village).

The results show that 98% and 98.2% of the targeted children received treatment at C1 and C4, respectively; 78.8% presented evidence of treatment (cards or empty drug packs) at C1. At C4, 65% of children (73) who did not receive treatment were ineligible. During this cycle, only 57% had cards and 75.6% of the cards were correctly filled in on Day2 and Day3 by the parents.

We also note that 97.1% of the children took the treatment at Day2 and Day3 according to the parent’s declaration at C4 and 97.4% at C1. 2.4% of the parents did not give the medication at Day2 or Day3 compared to the fourth visit. Also, 99.9% (2274) of the parents were satisfied with the SMC at C4, they were 99.7% at C1.

These results show an overall good implementation   in accordance with the guidelines of SMC. We note a reduction of lethality in many districts like Kampti (78%).  However, challenges exist such as outreach communication which needs to be improved, availability and proper storage of treatment cards, referral of cases requiring to be seen by a health care worker. Independent monitoring shows a better figure of the SMC coverage and allow the implementation of qualitative SMC campaign.

Ousmane Badolo, Mathurin Bonzi, Moumouni Bonkoungou, Youssouf Sawadogo, Gauthier Tougri, Mathurin Dodo, Gladys Tetteh, William Brieger reported on Early Seasonal Malaria Chemoprevention (SMC) Implementation Contributed to Reducing Malaria Incidence in Sud-Ouest Region in Burkina Faso at the 2022 Annual meeting of the American Society of Tropical Medicine and Hygiene in Seattle.

They explained that in Burkina Faso, malaria remains a major public health problem. According to 2020 health statistics, malaria accounted for 40% of health service consultations, 54% of hospitalizations, and 27% of deaths. Children under 5 years of age account for 72% of malaria deaths.

To help reduce this burden, the Ministry of Health, with the support of its partners, has organized annual Seasonal Malaria Chemoprevention (SMC) campaigns since 2014 during the high malaria transmission period (July, August September, and October). In 2021, the U.S. PMI Impact Malaria project provided support to the National Malaria Control Program to implement SMC in 19 districts from three regions (Centre-Est, Centre-Ouest, and Sud-Ouest).

One of the innovations of the 2021 SMC campaign was the introduction of five cycles in 7 of these 19 districts, compared to four cycles elsewhere. Therefore, SMC started earlier (in June) while all the others started in July. We compared the incidence of malaria (in the 5 districts of the Sud-Ouest region) in 2020 to that of 2021 when the SMC started earlier.

The malaria incidence is estimated based on the weekly disease surveillance form where the number of malaria cases is recorded, using updated population census data as a denominator. In 2020, the average malaria incidence from May 31 to October 6 in the Sud-Ouest region was 51.44/1000. In 2021, during the same period malaria incidence was 40.94/1000 (a decrease of 20%) The SMC coverage was 103% and 104% respectively in 2020 and 2021.

Starting SMC early can contribute to reduced malaria incidence but key challenges need to be addressed: i) Underestimation of the target population due to IDPs and gold miners; ii) youngest children are with their mothers on the farm so cannot be found at home; iii) insufficient cards for the SMC.

Thierry Ouedraogo, Ousmane Badolo, Youssouf Sawadogo, Moumouni Bonkoungou, Francine Ouedraogo, Mathurin Bonzi, Gauthier Tougri, Alidou Sawadogo, Mathurin Dodo, Gladys Tetteh, and William Brieger report on Reduction in Malaria Case Fatality Rate After Implementation of an Emergency Plan for Improved Case Management in the Bittou Health District, Burkina Faso at the Annual Meeting of the American Society of Tropical Medicine and Hygiene in Seattle.

They observed that in Burkina Faso, malaria remained the leading cause of death between 2014 and 2021. In the Centre Est region, uncomplicated malaria cases among children under five years of age were 11% of the country’s total (3,679,128 cases) and severe malaria cases were 9% of the country’s total (211,093 cases) in 2014. This region, is subdivided into 7 health districts including Bittou.

In 2014, the malaria case-fatality rate (CFR) among children under five years of age in Bittou (1.39%) was higher than the average for all districts in the Centre Est region (1.08). To remedy this situation, the Bittou health district management team (HDMT) implemented an emergency plan in 2016.

The plan included five components: i) sensitization of health facility staff to enable the rapid referral of severe malaria cases to the district hospital (CMA); ii) reorganization of CMA pediatric emergency management to make a physician the first point of contact; iii) Ensuring availability of supplies for severe malaria case management, including the availability of blood; iv) daily medical check-ups of hospitalized patients, and v) reinforcement of skills all HFs.

Other improvements in the health system that were introduced around the same time, but were not part of the emergency plan, included: i) free care for children under 5 years of age; ii) municipal financing of ambulance fuel for transferring patients referred; iii) free blood collection; iv) free telephone calls between the health structures; v) the presence of 5 doctors at the CMA, and vi) coaching and increased dynamism of the HDMT.

After implementation of the emergency plan, the malaria CFR in Bittou went from 1.39% in 2014, and 1.52% in 2015 to 0% in 2016 and 2017, 0.2% in 2018, 0% in 2019, 0.07% in 2020 and 0.05% in 2021. Malaria control remains a challenge in Burkina Faso. However, the improved CFRs seen in Bittou show that effective involvement of HDMT could potentially contribute to substantial reductions in malaria mortality.

Charity Anoke, Bright Orji, Emily Bryce, Elizabeth Oliveras, Joseph Enne, Elizabeth Njoku, Lawrence Nwankwo, Emmanuel Ugwa, Bartholomew Odio, Herbert Onuoha, Christina Maly, Emmanuel Otolorin, Elaine Roman, and Oniyire Adetiloye are presenting a poster for the TiPToP project at the American Society of Tropical Medicine and Hygiene’s Annual Meeting in Seattle. Below is the evidence from maternity record booklets in Ohaukwu, Ebonyi State Nigeria.

Nigeria has the highest malaria burden globally, contributing to 31.9% of global malaria deaths, and is one of the two countries with the greatest burden of malaria during pregnancy. According to the 2018 Nigeria Demographic and Health Survey (DHS), even though up to 57% of pregnant women attend ANC four or more times, only 17% received three or more doses of IPTp as recommended by the WHO.

Nigeria supported this demonstration project of CHWs in delivering intermittent preventive treatment of malaria in pregnancy (IPTp) at the community-level, complementing IPTp at antenatal care (ANC) in three districts. Data were extracted from 735 maternity record booklets (MRB) at 25 public health facilities in Ohaukwu for women presenting for ANC between April and September of 2019. The MRB allowed for the longitudinal analysis of client-level data that is not available from routine data sources.

Sixty percent of women received IPTp doses only in the community, while 28% received IPTp only at ANC and 12% received IPTp in both locations. One-way ANOVA and post-hoc Tukey tests were used to examine the difference in mean number of ANC visits and number of IPTp doses between the three groups. The mean number of ANC visits was significantly higher in the group of women receiving IPTp at both locations compared to those only receiving IPTp in the community (0.89 ± 0.18 visits, p<0.01) and those only receiving IPTp during ANC (0.61 ± 0.20 visits, p<0.01).

There was no statistically significant difference in the mean number of ANC visits between the groups receiving IPTp only in one location (0.29 ± 0.13 visits, p=0.077). The difference in number of doses was statistically significant across all groups, whereby women in the facility-only group received the fewest IPTp doses. Receipt of IPTp in both locations was associated with both greater numbers of ANC visits and IPTp doses. Only receiving IPTp in the community was not associated with a decrease in ANC attendance.

These data suggest complementing ANC-based IPTp distribution with community-based distribution is beneficial.

Moumouni Bonkoungou, Ousmane Badolo, Mathurin Bonzi, Youssouf Sawadogo, Andre Kone, Thierry Ouedraogo, Gauthier Tougri, Mathurin Dodo, Edward Kenyi, Gladys Tetteh, and William Brieger working with the US PMI Impact Malaria project implemented Seasonal Malaria Chemoprevention (SMC) in collaboration with the National Malaria Control Program (NMCP) of Burkina Faso in 3 regions. Their findings are seen below and are presented at the Annual Meeting of the American Society of Tropical Medicine and Hygiene in Seattle.

According to health statistics for 2020, in Burkina Faso, malaria accounts for 40% of medical consultations and 27% of deaths. Children under 5 years of age account for 72% of malaria deaths. 

In 2021, the SMC consists of the administration of three days of monthly treatments of amodiaquine plus sulfadoxine-pyrimethamine to all eligible children (3-59 months of age) during the high malaria transmission season (June to October). The objective is to maintain therapeutic concentrations of these antimalarials during the period of high transmission. 

In 2021, 19 of 70 health districts (27%) were supported by the project to implement SMC with more than 838,000 children under 5 years treated, including 180,000 from the Sud-Ouest region (Dano, Batie, Kampti, Gaoua, and Diebougou health districts). In this region of high rainfall, the number of severe malaria cases in children under 5 years decreased from 17,760 in 2017 (before SMC) to 14,609 in 2021 with SMC after 4 years of SMC implementation, i.e., a reduction of 17%. 

The number of malaria deaths also decreased from 133 in 2017 (before SMC) to 118 in 2021, a reduction of 11%. Kampti health district recorded the highest reduction of deaths of 78% [33 to 7 deaths] between 2017 and 2021 and Dano district had a reduction in severe malaria cases by 28% between 2017 and 2021. 

The main challenges with SMC include a delay in referral of fever cases by community distributors to health facilities during the campaign, management of vomiting during the 2nd or 3rd dose, and failure to retain the treatment cards by the parents. Seasonal Malaria Chemoprevention is a proven intervention and appears to be an important

component of the malaria prevention strategy in Burkina Faso but consideration should be given to address ongoing implementation challenges.

Marwa Ramadan of the Alexandria Faculty of Medicine, Alexandria, Egypt and William Brieger of the Johns Hopkins Bloomberg School of Public Health are presenting this information at the Annual Meeting of the American Society of Tropical Medicine and Hygiene in Seattle.

Studies have highlighted the potential impact of conflict and displacement on malaria prevention and mitigation efforts, but few investigated the effect of subnational conflict intensity on access and utilization of mosquito nets in fragile countries.

This study bridges the gap by applying a conflict intensity lens to the analysis of access and utilization of Insecticide Treated Nets (ITN) in two conflict-affected fragile states (Nigeria and Democratic Republic of Congo (DRC)), where at least 45 % of global malaria deaths occur.

We used the Demographic health survey (DHS) and the Uppsala Conflict Data Program for information on access and utilization of nets and conflict events respectively. Access was defined as the percentage of population with at least one ITN per 2 household members, while utilization was defined as the percentage of population who slept under an ITN the night before the survey in households with at least 1 ITN.

To define conflict intensity, we linked household clusters to conflict events within a 50 km distance using ArcGIS. Conflict intensity was then categorized into medium or high intensity conflict and no or low intensity conflict using a cut-off of 2 or more deaths per 100, 000 population per cluster. Access and utilization of ITNs was compared by conflict intensity at the household cluster level.

Analysis of data from 281,689 individuals living in 58,183 households revealed that 42.8% (CI: 42.3 – 43.3%) and 39.9% (CI: 39.5 – 40.1%) of members living in neighborhoods with medium and high intensity conflict in DRC and Nigeria respectively had access to ITNS compared to 47.9% (CI: 47.6 – 48.1%) and 51.0% (CI: 50.8 – 51.2%) in no or low intensity conflict.

Similarly, 65.1% (CI: 64.3 – 65.9%) and 62.8% (CI: 62.3 – 63.3%) of those living in medium or high intensity conflict in DRC and Nigeria respectively utilized ITNS compared to 69.2 % (CI: 68.8 %-69.6 %) and 65.7% (CI: 65.4-66.0%) in no or low intensity conflict.

National malaria control programs must consider that access and utilization of ITNS are statistically significantly lower in neighborhoods with medium or high intensity conflict and target supporting interventions accordingly.